Myriad Genetics Inc.

MYGN | NASDAQ

Price Alert Chart Builder DCF Calculator

$4.01

+$0.12 (+3.08%)

At close: Sep 21, 2026, 4:00 PM ET

$4.01

$0 (0.00%)

After-hours: Sep 21, 2026, 7:30 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+3.08%

(1D)

Rating

Updated: Sep 19, 2026

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $378.74M

1D Range

3.87 4.04

52W Range

2.74 8.59

Valuation (TTM)

PE -3.37

PB 1.25

EV/EBITDA -8.16

Valuation (NTM)

Forward PE 36.09

Forward PEG 0.15

Price Target $2.90

Cash Flow

FCF Yield -0.3%

SBC Adj. FCF Yield -4.3%

SBC Impact -1363.6%

Margins

Gross Margin 68.8%

Operating Margin -11.6%

FCF Margin -0.1%

Growth (CAGR)

Revenue 3Y | 5Y 4.9% | 9.7%

Dil EPS 3Y | 5Y 12.8% | -14.9%

FCF 3Y | 5Y 111.0% | 42.2%

Returns

ROA -17.6%

ROE -32.6%

ROIC -19.1%

Financial Health

Net Debt

$95.3M

Current Ratio 2.21

Interest Coverage -6.01

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomic...

Sector Healthcare

Industry Medical - Diagnostics & Research

Employees 2,700

IPO Date Oct 5, 1995

Website www.myriad.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 2, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Hold

Price Target

Downside

-25.19%

Buy (0)

Hold (2)

Sell (1)

Analyst Details ➞